BioCardia Presents Q1 2023 Financial Results and Corporate Update…

BioCardia Presents Q1 2023 Financial Results and Corporate Update…


SUNNYVALE, Calif., May 3, 2023 (GLOBE NEWSWIRE) — BioCardia®, Inc. BCDA, a developer of cellular and cell-based therapeutics for the treatment of cardiovascular and pulmonary diseases, announced today that it will report its financial results for the three months ended March 31, 2023, on Wednesday, March 10, 2023 at 4:30 p.m am ET. After management’s formal comments, there will be a question-and-answer session.

Participants can register for the conference by navigating to Please note that registered participants will receive their dial-in number upon registration. For those who have not registered to hear the call over the phone, those interested should call 1-833-316-0559 within the US and 1-412-317-5730 for international callers. All callers should dial in approximately 10 minutes prior to the scheduled start time and request to join the BioCardia call. The conference call will also be available via a live webcast, which can be accessed via the following link:

A webcast replay of the call will be available approximately one hour after the end of the call through August 10, 2023 at the links provided above. A telephone replay of the call is available through May 24, 2023 and can be accessed by calling 1-877-344-7529 (Domestic), 1-412-317-0088 (International), or 855-669-9658 (Canada). . with access code 8791101.

About BioCardia®
BioCardia, Inc., headquartered in Sunnyvale, California, is a developer of two biotherapeutic platforms – autologous bone marrow-derived mononuclear cell therapy CardiAMP for cardiovascular indications and NK1R+ allogeneic bone marrow-derived mesenchymal stem cell therapies for cardiovascular and pulmonary diseases. Underlying these platforms are four product candidates, each with the potential to deliver millions of…


Source story

More to explorer